Pullan's Pieces, Part II - A Business Development View of the CNS Landscape
Central nervous system disorders include diseases with millions of patients (such as schizophrenia, Alzheimer’s and depression), and they also include rare diseases, such as SMA (spinal muscular atrophy), Friedreich Ataxia, and ALS (amyotrophic lateral sclerosis). Many CNS diseases have no treatments or unsatisfactory treatments, and many of them place a tremendous burden on families and society because they result in a “loss of self.”
In this segment of Pullan’s Pieces, business development consultant, Linda M. Pullan, PhD, builds on the Pullan’s Pieces newsletter infographics and presents an overview of the current CNS drug market landscape and how it compares to other therapeutic areas. She also briefly touches on top companies and top drugs, new indications, and trends in VC, M&A and licensing deals in the CNS space.
In this white paper, you'll learn:
- How today's CNS market compares to other therapeutic areas
- The unmet needs
- Who are the major players are and what they are developing
- How the current CNS pipeline stands
- What are the deals like and the stage of development they are taking place
- What you can expect over the next few years
- Plus more.
This white paper is based on a one-hour webinar where Linda provided a comprehensive overview of today’s CNS landscape, and offered her clarity and perspectives on many of its complexities and nuances.
Download the white paper to learn more.
Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.